Coartem® Dispersible

Novartis

Product category
  • 3-day cure, artemisinin-based combination therapy (artemether-lumefantrine)
Therapeutic indication
  • Treatment of children >5kg and <25kg with uncomplicated P. falciparum infection (including mixed infection)

Dosing
  • Twice-daily for 3 days

Efficacy
  • 28-day cure rate (PCR-corrected) 94%–98%

  • 42-day cure rate (PCR-corrected) 96%–100%

Key features
  • Dispersible, cherry-flavour taste-masked formulation dissolves in 10mL of water, eases paediatric administration

  • Two-year shelf life
Challenges
  • Food effect: should be taken with food or drink rich in fat

  • Twice-daily dosing

Status
  • Approved 2008 SwissMedic; 2012 EMA

  •  

    Approved in over 50 endemic countries
  • 400 million treatments distributed
MMV Project Director
  • Adam Aspinall